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The 7th Osteoarthritis Research Society International (OARSI) International Workshop on Osteoarthritis
Imaging was held in Reykjavik, Iceland, from July 9e12, 2014; attracting attendees from academia,
pharmaceutical and Magnetic resonance imaging (MRI) industries, as well as a large number of young
investigators. The Workshop program consisted of six modules, including imaging in osteoarthritis (OA),
imaging and pain in OA, new techniques in imaging, risk factors and structural outcomes, anti-nerve
growth factor (a-NGF) therapy, and joint replacement. A wealth of data was presented from OA re-
searchers from all over the world and participants gained insightful knowledge on up-to-date research
work focusing on imaging of OA. This paper presents a summary of the salient points from the workshop.
Conclusions: Identifying the appropriate imaging modality and parameters will be critical for ensuring
responsive, reproducible and reliable outcomes for clinical trials. Continued efforts from the OA research
community are needed to establish the most effective use of imaging in OA clinical trials, including anti-
NGF therapy and joint replacement trials, and to validate newer imaging techniques such as composi-
tional MRI for use in the future clinical trials.
© 2015 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
The 7th International Workshop on Osteoarthritis Imaging was
held from July 9the12th, 2014, at the University of Iceland, Rey-
kjavik, Iceland. A record-breaking number of abstracts were
received, and 92 representatives from 14 countries attended. These
included representatives from academia and the private sector.
Participation of a large number of young investigators was partic-
ularly encouraging. The Workshop program consisted of six mod-
ules, including 1) imaging in osteoarthritis (OA), 2) imaging and
pain in OA, 3) new techniques in imaging, 4) risk factors and
structural outcomes, 5) anti-NGF therapy, and 6) joint replacement.
A wealth of data, particularly from the Osteoarthritis Initiative
(OAI), was presented with ample opportunities for questions,: A. Guermazi, Quantitative
iversity School of Medicine,
zi).
ternational. Published by Elsevier Ldiscussions and debates. This paper summarizes the information
presented at the workshop. The participants gained valuable
insight on cutting edge research on imaging of OA.
Imaging and pain
The ﬁrst twomodules of the workshop focused on issues related
to imaging and pain in OA. David Felson discussed the role of im-
aging epidemiological studies and clinical trials of OA, and identi-
ﬁed that the goals of imaging should include identiﬁcation of
treatment targets, characterization of imaging biomarkers that
change with treatment, discovery of treatable ﬁndings and detec-
tion of joints at high risk of rapid structural deterioration and pain
that might warrant special treatment. He highlighted the impor-
tance of focusing on innervated structures such as bone and
synovium and conducting studies of persons with early symptoms
using dynamic imaging and novel imaging modalities that offer
insights into pain/treatment effects. Kent Kwoh described how
imaging has contributed to our understanding of pain in OA.
Currently available tools for pain assessment in knee OA include thetd. All rights reserved.
Fig. 1. Standard 2D intermediate weighted fat saturated turbo spin echo image in the
axial plane. The patellar cartilage is visualized with intermediate signal intensity
compared to bone and intra-articular joint ﬂuid. Superﬁcial cartilage ﬁssuring is
observed at the lateral facet (large arrow). In addition there are intrachondral areas of
hyperintensity likely reﬂecting early degeneration, although relevance of these signal
changes is still under debate. (Image courtesy of Dr. John Carrino, Hospital for Special
Surgery, New York, NY).
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WOMAC pain scale and Intermittent and constant OA Pain (ICOAP).
Morphologic features that have been demonstrated to be associ-
ated with knee pain in OA include bone marrow lesions, synovitis/
effusion, meniscal damage and subchondral bone. He highlighted
the concept that knee pain in OA tends to be transient early in the
disease course and then becomes persistent as the disease
progresses.
Several abstracts were presented regarding imaging and pain in
OA. Using a new semi-automated measurement technique, Lynch
and colleagues demonstrated hips with deﬁnite radiographic hip
OA at baseline showed relatively high rates of >0.7 mm minimum
joint space width (JSW) loss, with an average rate of 0.15 mm per
year loss (with standardised responsemean (SRM)¼ 1.0) in 128 OAI
participants1. Kwoh and colleagues performed a nested case-
econtrol study and showed a new knee injury or surgery is asso-
ciated with increased risk of worsening of MRI structural features,
particularly meniscal damage and Hoffa synovitis (i.e., inﬂamma-
tory changes in the Hoffa fat pad), as well as increased risk of
incident radiographic OA2. A longitudinal study conducted by
Roemer and colleagues reported that the presence of structural
MRI-detected joint damage increases the risk of incident radio-
graphic OA 1 year after the time of MRI examination. When
compared to knees that do not show any of the analyzed features
(i.e., bone marrow lesions, cartilage lesions, meniscal tear, macer-
ation or extrusion, and synovitis/effusion) during the observation
period, knees with presence of MRI features at any of the analyzed
time points exhibited an increased risk of radiographic OA. Thus,
the joint structural status 1-year prior seems to be the most rele-
vant risk factor in regard to radiographic OA development3.
Pain in knee OA is an important issue in clinical management of
OA, and thus attracts appropriate attention in OA research. The Knee
Pain Map4 is a tool which can reliably record localized and regional
knee pain in individuals with OA, but thus far has not been widely
utilized. Using the data from the OAI and a quantitative MRI
approach, Cotofana and colleagues evaluated the spatial pattern of
structure-pain-relationships in knee OA5. This study showed that
the speciﬁc locations of denuded areas of subchondral bone were
associated with different knee pain locations. For example, medial
regional pain was associated with denuded areas of subchondral
bone in the medial central (weight-bearing) femur but not in the
lateral one. The MRI OA Knee Score (MOAKS) is a relatively new
semi-quantitative scoring system that enables whole-organ
assessment of knee OA6. Using the MRI deﬁnition of knee OA7 and
the data from the Rotterdam Study, Schipof and colleagues
demonstrated women with bilateral knee OA have lower Knee
injury and Osteoarthritis Outcome Score (KOOS) for all subscales
including pain, compared to womenwith unilateral OA and no knee
OA8e10. The MRI deﬁnition for tibiofemoral OA was deﬁned as the
presence of a deﬁnite osteophyte and full-thickness cartilage loss, or
as a deﬁnite osteophyte or full-thickness cartilage loss plus two of
the following features: (1) subchondral BML or cyst not associated
with meniscal or ligamentous attachments, (2) meniscal subluxa-
tion, maceration or degeneration (including a horizontal tear), (3)
partial-thickness cartilage loss, or (4) bone attrition. The ﬁndings of
this study imply that OA researchers should be aware that having
unilateral OA vs bilateral knee OA can be a potential confounding
factor in analyses deploying semi-quantitative MRI and KOOS-based
clinical outcome. Also using the MRI deﬁnition of OA7, Runhaar and
colleagues showed the presence of tibiofemoral MRI OA at baseline
signiﬁcantly increased the risk for incident radiographic OA after 30
months amongst middle-aged overweight and obese women
without clinical and radiographic knee OA at baseline11. Such in-
formation may be helpful for patient selection for prevention trials
involving people at high risk of developing knee OA.To date, patellofemoral joint (PFJ) OA has received little epide-
miologic attention despite affecting the majority of persons with
symptomatic knee OA. Ratzlaff and colleagues conducted a cross-
sectional study in 115 subjects from the baseline data of the OAI
Progression Cohort to determine the relationship of bone marrow
lesion volume and weight-bearing pain for the tibiofemoral joint
(TFJ) and PFJ separately, and to describe the medial-lateral distri-
bution of bone marrow lesions in the PFJ12. Evidence for a strong
relationship between stair-climbing pain and bone marrow lesion
volume in knee OA, particularly in the PFJ, was demonstrated.
Further work on the longitudinal relationship between PFJ bone
marrow lesion volume and pain is needed.New techniques in imaging
Module 3 focused on technologic advances in the ﬁeld of im-
aging in the context of OA research. John Carrino introduced the
topic with a comprehensive overview on recent technical de-
velopments in the ﬁeld of musculoskeletal MRI. The focus of his
presentation was two-dimensional (2D) vs three-dimensional (3D)
MRI especially in regard to the visualization of cartilage, evolution
of 3T MRI and ultrashort echo time (UTE) imaging and its potential
applications (Figs. 1e3)13.
MRI has become the most important imaging tool in the eval-
uation of different joint structures in knee OA in both, clinical and
research environments. For comprehensive joint assessment in the
context of OA, commonly 2D ﬂuid sensitive turbo spin-echo (TSE)
sequences are applied14e16 (Fig. 1). In contrast, most 3D MRI tech-
niques used in OA research are gradient recalled-echo (GRE) se-
quences that can be acquired with isotropic or nearly isotropic
resolution, which reduces partial-volume artifacts while acquiring
very thin continuous sections through the joint. However, 3D GRE-
type sequences are also time-consuming, and although it is
possible to reconstruct the source acquisition inmultiple planes, 3D
Fig. 2. Focal cartilage defects. A. Sagittal dual echo at steady state (DESS) image shows a signal change at the posterior aspect of the lateral femoral condyle but no discrete cartilage
defect (arrow). The articular surface appears to be intact. B. The corresponding sagittal fat-suppressed proton density-weighted image clearly shows a deﬁnite superﬁcial focal
cartilage defect not extending to the subchondral bone. Focal cartilage defects are the earliest manifestations of pre-radiographic osteoarthritis. This examples illustrates the
inferiority of gradient echo sequences for the depiction of focal cartilage defects.
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not allow for accurate assessment of other important joint struc-
tures such as the menisci, ligaments, and subchondral bone17e19. In
addition, 3D GRE-type sequences are inferior in depicting focal
cartilage defects, which are likely to be the ﬁrst manifestations of
structural damage in early or pre-radiographic OA20,21 (Fig. 2). 3D
TSE MRI techniques have been recently introduced and applied to
obtain images of the knee joint, which can produce images with SE
IW contrast, the most commonly used tissue contrast in musculo-
skeletal imaging17,22,23,24. An overview of the commonly used
different 3D MRI sequences in the musculoskeletal system is pre-
sented in Table I.
Technologic developments in hardware and software in recent
years have led to systems with increased ﬁeld strength (i.e., 3TMRI)
and improved gradient performance. 3T systems provide a nearly
two-fold increase in signal-to-noise ratio (SNR)25. The increase in
SNR can be used to increase the speed of imaging, achieve a better
contrast-to-noise ratio, or improve spatial resolution by usingFig. 3. Comparison of 2D turbo spin echo vs 3D turbo spin echo. A. Sagittal fat suppressed im
central weight-bearing femur (small arrows). In addition there is a large bone marrow lesio
image (SPACE) shows the superﬁcial cartilage defects with comparable conspicuity (small a
which is a result of increased sensitivity of 3D sequences to magnetic susceptibility.smaller section thickness. However, MR imaging at 3T is more
affected by some artifacts, such as susceptibility artifact and
chemical shift misregistration, than that acquired at 1.5T26,27.
Discussing other recent technical developments, Dr. Carrino
further focused on UTE imaging28. UTE pulse sequences enable T2-
and T2* weighted imaging of these tissues by using an extremely
short TE29. There have been attempts to use UTE in evaluation of
the deep layers of cartilage30, but its correlation with aspects of
cartilage composition still needs to be validated31. In the past,
when gradient inserts were required to obtain the necessary very
short initial ﬁrst echo sampling for effective T2* ﬁtting of very
short T2 species, such as tendon, ligament or cortical bone, it was
thought that development of specialized MR equipment would be
required for deployment of UTE to overcome technical challenges
affecting image quality32. Today, current gradient performance is
sufﬁcient and UTE imaging does not require specialized coils or
hardware, and utilizes standardized software and post processing
algorithms.age of the medial compartment of the knee shows superﬁcial cartilage damage in the
n at the posterior tibia (large arrow). B. Sagittal reformation of fat suppressed 3D TSE
rrows). The bone marrow lesion on the 3D image is depicted with less signal intensity,
Table I
Selected three-dimensional MRI pulse sequences commonly used in the musculo-
skeletal system
Sequence Fluid signal
intensity
Vendor Abbreviation/Acronym
GE
Healthcare
Siemens
Healthcare
Philips
Healthcare
Spoiled gradient Echo Low SPGR FLASH T1 FFE
Coherent gradient echo High GRASS GRE FFE
Steady-state free
precession
High SSFP PSIF T2 FFE
Balanced steady-state
free precession
High FIESTA,
VIPR-SSFP
True FISP Balanced
FFE
Driven equilibrium High DEFT n/a n/a
Dual-echo in steady state High n/a DESS n/a
Multi-Echo Data Image
Combination
High MERGE MEDIC M-FFE
3D fast spin echo High CUBE SPACE VISTA
SPGR ¼ spoiled gradient-recalled echo, GRASS ¼ gradient-recalled acquisition in
steady state, GRE ¼ gradient-recalled echo, SSFP ¼ steady-state free precession,
PSIF ¼ reverse fast imaging with steady-state free precession, FIESTA ¼ fast imaging
employing steady state, VIPR¼ vastly undersampled isotropic projection, FISP¼ fast
imaging with steady-state precession, DEFT¼ driven equilibrium Fourier transform,
DESS ¼ dual-echo in steady state, XETA ¼ extended echo-train acquisition,
SPACE ¼ sampling perfection with application-optimized contrast with different
ﬂip-angle evolutions, FFE ¼ fast ﬁeld echo, VISTA ¼ Volumetric Isotropic T2w
Acquisition.
Table adapted from: Naraghi A, White LM. Three-dimensional MRI of the muscu-
loskeletal system. AJR Am J Roentgenol 2012; 199(3):W283e293.
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colleagues introducing an automated approach for segmentation of
bone and cartilage of the knee based on 3T MRI on 172 subjects
from the OAI, reporting high analysis accuracy of cartilage sub-
plates33. The authors concluded that completely automated quan-
titative knee joint sub-plate analysis is possible with high accuracy.
Segal and colleagues presented preliminary data on 20 subjects
from the MOST study on the correspondence between the mean
medial tibiofemoral JSW obtained from ﬁxed ﬂexion radiographs
and the distribution of JSW at each of corresponding locations on
3D standing computed tomography (CT)34. The authors found that
rather than the minimum JSW, mean JSW values represent areas of
the joint in the 60the80th percentiles of the 3D JSW at each
mediolateral location, which they interpreted as likely due to the
overlap of anatomy obscuring portions of the joint on radiographic
projections. Wang and colleagues presented on changes in menis-
cal T1r and T2 quantiﬁcation in patients with acute anterior cru-
ciate ligament (ACL) injuries. They assessed correlations of these
changes to MR clinical grading and patient-reported outcomes35.
The authors found that acute ACL injuries lead to signiﬁcantly
increased T1r and T2 values in the meniscus. Interestingly, signif-
icantly elevated T1r and T2 values were also found in ACL-injured
knees without meniscal tears compared to controls. Crema and
colleagues presented on associations of baseline delayed gadolin-
ium enhanced MRI of cartilage (dGEMRIC) as well as changes in
dGEMRIC indices with cartilage loss in the same region of the knee
over 1 year, in a sample of middle-agedwomenwith knee OA36. The
authors found no signiﬁcant associations between change in
dGEMRIC indices over time and cartilage loss. A cut-off value of
dGEMRIC predicting cartilage loss could not be established
concluding that the predictive effect of changes in dGEMRIC on
cartilage loss in the tibiofemoral compartments over 1 year could
not be demonstrated in this sample of middle-aged women.
In addition, two presentations focusing on technical de-
velopments were part of other sessions but warrant mentioning.
Engelke and colleagues presented on changes of subchondral
trabecular architecture which may be an important indicator of
progression in knee OA37. As the quantiﬁcation of parameterscharacterizing trabecular structure in vivo is difﬁcult due to the
limited spatial resolution of available CT or MR imaging equipment
the authors assessed texture parameters to quantify OA related
changes of subchondral trabecular architecture using whole body
clinical quantitative computed tomography (QCT) and compared
these with results obtained from high-resolution peripheral quan-
titative computed tomography. The authors concluded that texture
parameters obtained in vivo fromwhole body QCT images should be
usable to characterize changes of the subchondral trabecular ar-
chitecture under OA progression. Pedoia and colleagues presented
work on statistical shape modeling38. The authors used ACL injury
as a model with the aim to apply statistical shape modeling to MRI
in order to analyze the shape of the tibia and femur in patients with
ACL injuries and examine for shape differences between control
and injured groups. The authors found signiﬁcant shape differences
between the ACL-injured knees and control knees at baseline,
suggesting a common shape feature that may predispose these
knees to injury and concluded that bone shape quantiﬁcation has
the potential to identify speciﬁc risk factors for injuries.
Risk factors and structural outcomes
Module 4 focused on risk factors and structural outcomes in OA
and comprised a heterogeneous set of lectures on various meth-
odological aspects and tissues involved in OA progression.
Extending on his previous publications39 Yuqing Zhang introduced
the topic by highlighting the statistical challenges in studying risk
factors of OA progression in epidemiological studies. Awell-formed
and testable hypothesis should be developed before any analysis is
conducted and the intent of the research question and its corre-
spondingmeasure should be clearly deﬁned. Dr. Zhang suggests the
use of “incident” rather than “prevalent” exposure, i.e., new user or
initiation of exposure (e.g., “does initiation of bisphosphonate use
protect from radiographic OA progression among subjects with
mild/moderate knee radiographic OA”). He concluded that more
studies are needed to better understand the natural history of OA
development, and observational studies of chronic risk factors such
as body mass index or bone mineral density on knee radiographic
OA progression among knees with mild/moderate knee radio-
graphic OA remains challenging.
Four abstracts were then represented in the following session,
with Ruhdorfer and colleagues reporting longitudinal ﬁndings on
thigh muscle, subcutaneous fat, and inter-muscular fat cross-
sectional areas in OAI participants with chronic knee pain,
compared with painless control participants. Based on previous
cross-sectional studies on the effect of pain on thigh muscle cross-
sectional areas and strength40,41 they found a signiﬁcant decrease
in quadriceps muscle cross-sectional areas in participants with
continuously high levels of knee pain (i.e., NRS > 4) over 4 years,
and a signiﬁcant increase in subcutaneous and inter-muscular fat.
The increase in thigh fat tissue content was more highly correlated
with change in body weight than with that of quadriceps muscle
loss.
A study by van Meer and colleagues showed that, over 2 years
following ACL rupture, 27% of the patients displayed an increase in
lateral tibiofemoral cartilage lesion semi-quantitative MRI scores,
whereas only 12% showed progression in the medial tibiofemoral,
and only very few progressed in the patellofemoral compartment.
The progression of cartilage lesions was associated with joint
effusion, bone marrow lesions, and meniscal tears observed after
injury. These imaging features may hence be useful in the clinical
management of patients after ACL rupture, as it is well known that
some, but not all patients develop knee OA after trauma.
Maschek and colleagues reported on the long term changes and
measurement variability of quantitative cartilage thickness
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recent reports on 1 year change42, they found the variability of MRI
measures of cartilage thickness increased only slightly over 2, 3,
and 4 year observation periods. Interestingly, tibial cartilage dis-
played slight systematic thinning, and femoral cartilage slight
thickening with aging.
Donoghue and colleagues presented a novel manifold learning
approach to discover OA imaging biomarkers for the prediction of
joint function, with the speciﬁc goal of the study being to predict
the severity of the aggregated total WOMAC score in OAI partici-
pants by imaging biomarkers. Using automated algorithms, the
knee cartilage was “roughly” segmented using an atlas based
approach and was then divided into subregions. Low dimensional
representations of these subregions were computed, combined
with each other, and analyzed by principal component analysis. The
imaging biomarkers derived by this approach were found to
discriminate signiﬁcantly between OAI participants with low and
high WOMAC scores using linear discriminant analysis.
The topic of predicting clinical progression of knee OA by im-
aging also was a topic of module 6, with a particular focus on
incident joint replacement. Jeff Katz presented the socio-economic
relevance of total knee replacement (TKR)43. Dr. Katz explained that
an increasing trend in TKR utilization can be due to increasing
incidence and prevalence of knee OA, expanding indications to
younger and less functionally disabled patients, growing avail-
ability of orthopedic hardware, and changing patient preferences.
Frank Roemer reported on semi-quantitative MRI predictors of
intra-articular tissue pathology in the context of TKR44 and Felix
Eckstein spoke about quantitative MRI predictors during various
time periods preceding incident TKR45. Morphologic features on
MRI that predict TKR include bone marrow lesions, synovitis/effu-
sion, meniscal damage, bone shape/curvature and quantitative
cartilage thickness. Absence of these MRI predictors indicates good
prognosis in regard to need for TKR and may encourage patients
and physicians to optimize non-surgical therapy to delay the need
for TKR. Martin Englund discussed the role of the meniscus in
incident OA46,47. He explained that degenerative, largely non-
traumatic, meniscal tear or extrusion is part of the OA disease
process and can be seen with already incipient OA or those pre-
disposed to OA. Module 6 was completed with a presentation from
Michael Nevitt who described how to use large OA trials, such as
the OAI and the MOST study, to further study risk factors of both
structural and clinical progression of knee OA. Combining data from
these two large datasets is not straightforward due to heteroge-
neity of data including differences in risk factor prevalence and
outcomes. He described the importance of paying attention to
standardizing subjects, variables and analyses and the use of
research strategies to make the OAI and MOST studies more com-
parable before pooling data from these studies.Anti-NGF and osteoarthritis
Module 5 focused on recent developments of anti-nerve growth
factor (a-NGF) therapy in the clinical management of OA. Nancy
Lane gave a background on a-NGF therapy and presented results
from the placebo-controlled clinical trials including the non-
serious joint related adverse events. She also presented, on behalf
of Marc Hochberg, the adjudication process of one of the previous
a-NGF programs with results, conclusions and implications for
future sponsored trials. This introductionwas followed by Christine
West who presented on the clinical development of Tanezumab for
chronic pain, and by two additional presentations by Ali Guermazi
and Frank Roemer focusing on joint-related imaging ﬁndings with a
focus on relevance for eligibility and safety, and on the differencesbetween radiologic assessment in clinical trials of DMOAD efﬁcacy
and in a-NGF studies with a focus on eligibility and safety.
Recent literature evidence shows that a-NGF has both good
analgesic efﬁcacy and improves function in patients with OA and
low back pain48e52. However, despite initial promising data, trials
in OA were suspended in 2010 by the Federal Food and Drug
Administration (FDA) due to concerns over accelerated rates of OA
progression to total joint replacement particularly in the large
joints of the lower limb53,54. The observations about adverse events
in Tanezumab studies, one of the a-NGF compounds under inves-
tigation, led to a report on the process and results of the adjudi-
cation of these events55. These adverse events were observed in
patients using NGF-inhibitors alone, and more commonly in com-
bination with non-steroidal anti-inﬂammatory drugs (NSAIDs)
suggesting that the cumulative analgesic effect of two separate
classes of drugs prompted patients to permit increased joint
loading lacking the usual pain that would limit such pathologic
stress on an already damaged joint52,55. A signiﬁcant dos-
eeresponse relationship between incident rapid progressive OA
(RPOA) and increasing doses of tanezumab was observed, which
was greater when tanezumab was given in combination with
NSAIDs55.
Since a-NGF therapies offer potential as the ﬁrst new class of
analgesics for many years, future studies of a-NGF compounds will
require rigorous safety criteria. Imaging will play a crucial role in
future clinical trials to deﬁne eligibility of potential participants and
to monitor safety during the course of these studies. This will
require baseline and frequent follow-up radiographs of both, the
index joints and other large weight-bearing joints to identify par-
ticipants at risk for rapidly progressive OA and identify subjects on
study with adverse events such as rapid progressive OA, osteo-
necrosis or joint destruction so treatment can be discontinued.
Additional MRI examinations will be important during the course
of a study in cases of unexpected joint pain or swelling or in cases of
discrepancy between clinical symptoms, mainly pain and radio-
graphic ﬁndings53. While in OA efﬁcacy studies image acquisition
and evaluation is optimized for sensitivity to detect minor changes
between treated and non-treated subjects, in a-NGF studies the
focus is on early detection of diagnoses that either put a subject at
increased risk for an adverse outcome (eligibility) or may result in
withdrawal from treatment (safety), which may include assess-
ment of multiple joints per subject.
Debates
The ﬁnal presentations of the workshop were focused on debate
and speciﬁcally the challenges of a slowly progressive disease and
implications this has for making clinical trials more efﬁcient. The
ﬁrst debate was focused on the topic of “is MRI the next outcome
measure to be approved by the FDA-EMEA?” and debated by Jeffrey
Katz and David Felson.
Opening statements outlined the current regulatory stance of
both the FDA and EMA in regard to the wide acceptance of radio-
graphic JSN as the acceptable endpoint for assessment of structural
damage to support the argument against using MRI for OA clinical
trial outcomes. If a drug meets the pain endpoint then structure is a
secondary concern56e58. If it does not, then structure becomes the
primary outcome and the validity of structural outcomes as proxies
for symptomatic improvement or functional improvement become
paramount.
A number of arguments have been posed, both for the purpose
of this debate and by the regulatory authorities against MRI
including problems with inconsistent reliability, validity (i.e., some
studies report modest associations with clinical outcomes), pre-
dictive validity (i.e., longitudinal associations of structural changes
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nomenclature and variable of interest, much higher cost compared
to radiography, less availability/access to technology and obsoles-
cence of both hardware and software. It is also important to note a
number of strengths of plain radiographs including adequate reli-
ability59, modest responsiveness for studies >2 years of duration
comparable to MRI57,60,61 and standardization of outcome of in-
terest (i.e., JSN).
For those who are against inclusion of MRI as FDA-EMA
approved outcomes for OA clinical trials, it is important to note
that the concerns raised by regulatory agencies over the use of MRI
are largely due to lack of knowledge of the existing literature evi-
dence showing proven validity62, reliability and responsiveness61
of MRI in the context of imaging in knee OA research.
The disadvantages of radiography and the advantages of MRI
have been enumerated repeatedly63. This includes superior validity
and responsiveness of MRI. There is also substantive ongoing ac-
tivity addressing these concerns64. As a community we can assist
by: 1) working together to standardize approaches to aggregating
MRI data including across tissue domains (cartilage, bone marrow,
synovium, meniscus, etc), and across locations (compartments,
surfaces, regions, etc); and 2) synthesizing ﬁndings across diverse
designs e.g., FNIH study (cases deﬁned by JSN and symptom pro-
gression). At the end of this session of Debate, a resounding ma-
jority of the participants of the Workshop voted in support for
inclusion of MRI as an FDA-EMA approved outcome for OA clinical
trials.
The second debate was focused on the topic “Are we concep-
tualizing the best OA clinical trials?” and as one of the debaters was
unable to attend David Hunter turned this into an interactive ses-
sion with the audience to ascertain their perspectives on a number
of questions pertaining to this topic. We are all aware of the
numerous failures in the OA DMOAD trial space65 and the reasons
for these failures including the agent having no effect, having an
intolerable side effect proﬁle (e.g., MMP inhibitors), discordance
between structure and symptoms outcomes, the lack of progressors
in the selected participants (e.g., risedronate), selection of the
wrong structural endpoint (e.g., calcitonin met MRI endpoint but
not plain radiographic co-primary outcome), inability to distin-
guish active agents symptom beneﬁts from an effective placebo
(e.g., BMP-7) and failure of translation of preclinical work to the
human model.
The audience was asked a series of questions. The ﬁrst was:
“What available structural measure has the best measurement
performance (responsiveness, reliability and validity)?” and of the
available options: bone shape; quantitative JSW; semi-quantitative
BML; semi-quantitative cartilage; and quantitative cartilage thick-
ness. 72% (of 58 participants) chose the last option (quantitative
cartilage thickness).
The second question was: What joint tissue structure and its
change has the strongest relationship to symptoms and their
change? Of the options available, BMLs was selected most
frequently: meniscus (7%), synovitis (26%), BMLs (41%), effusion
(4%) and cartilage (22%).
When asked “are the eligibility criteria for existing DMOAD
trials recruiting persons whose disease is too late to modify”? 83%
responded ‘yes’. In response to “If you had to choose one research
priority from the following list which would it be”? The following
responses were obtained: 1) Classifying OA into more homogenous
phenotypes i.e., splitting (41%); 2) Focusing on early knee OA (24%);
3) Developing/further reﬁning methods for risk stratiﬁcation (0%);
4) Developing methods for tissue speciﬁc targeted treatment (35%).
When asked “Would you support trialling combination thera-
pies”? The options were: Yes-anti-catabolic and anabolic agent;
Yes-mechanical therapies (e.g., brace, joint distraction) andanabolic treatment; Yes-Other; and No. 60% of responders selected
the “mechanical therapies (e.g., brace, joint distraction) and
anabolic treatment”, i.e., the second option.
In response to “What is your top priority for DMOAD trial
method development”? The available options were: Qualiﬁcation
of an MRI (imaging) biomarker; Qualiﬁcation of a biochemical
marker; Maintaining the regulatory status quo; and, other. 74%
selected the ﬁrst option: Qualiﬁcation of an MRI (imaging)
biomarker.
Conclusions
This Workshop provided a unique opportunity for researchers,
regulatory agencies, interested members of pharmaceutical com-
panies and others to meet and have an in depth and open minded
discussion about the best ways to advance the ﬁeld of OA imaging.
Identifying the appropriate imaging modality and parameters will
be critical for ensuring responsive, reproducible and reliable out-
comes. Continued efforts from the OA research communities is
needed to establish the most effective use of imaging in OA clinical
trials, including anti-NGF therapy and joint replacement trials, and
to validate newer imaging techniques such as compositional MRI
for use in the future clinical trials. Lastly, we look forward to the 8th
Workshop which will be held in San Francisco, California, in
September 2015.
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